Form 4: Lantheus Holdings Executive Andrea Sabens Reports Stock Transactions

Andrea Sabens, Chief Accounting Officer of Lantheus Holdings, reports acquisition of common stock and stock options, along with adjustments related to performance-based restricted stock units (PSUs).

Summary

• Andrea Sabens, Chief Accounting Officer of Lantheus Holdings, reported transactions involving the company's stock.
• On March 1, 2024, Sabens acquired 5,685 shares of common stock and stock options for 3,368 shares at an exercise price of $64.64.
• These shares include 1,895 restricted stock units vesting over three years and 3,790 performance-based restricted stock units (PSUs) that cliff vest after three years, with the ultimate award ranging from 0% to 200% of the target based on performance.
• On March 4, 2024, Sabens acquired 5,817 shares of common stock due to the vesting of relative Total Shareholder Return PSUs, which vested at 200% of the target number of shares.
• Following these transactions, Sabens beneficially owns 69,905 shares of common stock and 3,368 stock options.
• The stock options vest in three equal annual installments starting March 1, 2025, and expire on March 1, 2034.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing, reporting stock transactions. It doesn't inherently convey positive or negative sentiment.

Positives

• The vesting of PSUs at 200% of the target indicates strong performance relative to the set goals.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedules of the restricted stock units and stock options provide a timeline for future equity compensation.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their transactions in the company's stock. It's a standard practice for publicly traded companies to ensure compliance with insider trading regulations.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their executives, ensuring compliance with SEC regulations.
• Equity compensation, including stock options and restricted stock units, is a common component of executive compensation packages in the pharmaceutical and biotechnology industries, aligning management's interests with those of shareholders.
• Vesting schedules and performance-based awards are also typical features of these compensation plans, incentivizing long-term value creation.

Stakeholder Impact

• The transactions reported in this filing provide transparency to shareholders regarding the equity holdings of a key executive.
• The vesting of PSUs based on performance aligns management's interests with shareholder value creation.

Key Dates